Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RIBBON-LA-01: Single-arm, Open-label, Phase 2 Trial of Tislelizumab and Metronomic Capecitabine as Maintenance Therapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

NCT06093061 is registered in ClinicalTrials.gov with National Cancer Centre, Singapore as lead sponsor.

NCT NCT06093061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06093061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RIBBON-LA-01: Single-arm, Open-label, Phase 2 Trial of Tislelizumab and Metronomic Capecitabine as Maintenance Therapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
Lead sponsor
National Cancer Centre, Singapore
Phase
Phase 2
Overall status
Recruiting
Start date
July 3, 2024
Completion date
October 31, 2029
Enrollment
53 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma